^
    Back
    Association details:
    Biomarker:PML-RARA T285I
    Cancer:Acute Promyelocytic Leukemia
    Drug:Venclexta (venetoclax) (Bcl2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Medicine (Baltimore)
    Title:

    Relapsed/refractory acute promyelocytic leukemia with RARA-LBD region mutation was salvaged by venetoclax

    Published date:
    12/03/2021
    Excerpt:
    The patient was diagnosed with L-type PML-RARα-positive APL, harboring a RARA-LBD region mutation...A complete hematologic response was achieved with VEN-based therapy...PML-RARA mutation analysis results were as follows: RARA-LBD area: c.854C>T; p.T285I (high mutation rate)...
    DOI:
    10.1097/MD.0000000000028076